

ToxCast Research Program Update


Keith Houck

*U.S. EPA, National Center for Computational Toxicology
Office of Research and Development*



Oakland, CA
04 Dec 2013

Tox21 Vision: Transforming Toxicity Testing



**National Center for Advancing
Translational Sciences (NCATS)**
<http://www.ncats.nih.gov/>






**SOURCE: Collins, Gray and Bucher (2008) Toxicology.
Transforming environmental health protection. ²
Science 319: 906**


ToxCast /Tox21 Overall Strategy

- Identify targets or pathways linked to toxicity (AOP focus)
- Identify/develop high-throughput assays for these targets or pathways
- Develop predictive systems models
 - *in vitro* → *in vivo*
 - *in vitro* → *in silico*
- Use predictive models (qualitative):
 - Prioritize chemicals for targeted testing
 - Suggest / distinguish possible AOP / MOA for chemicals
- *High-throughput Exposure Predictions (ExpoCast)*
- *High-throughput Risk Assessments (quantitative)*

Testing under ToxCast and Tox21

Chemicals, Data and Release Timelines


Set	Chemicals	Assays	Endpoints	Completion	Available
ToxCast Phase I	 293	~600	~700	2011	Now
ToxCast Phase II	 767	~600	~700	03/2013	12/2013
ToxCast Phase IIIa	 1001	~100	~100	Just starting	2014
E1K (endocrine)	 880	~50	~120	03/2013	12/2013
Tox21	 8,193	~25	~50	Ongoing	Ongoing



Pesticides, antimicrobials, food additives, green alternatives, HPV, MPV, endocrine reference cmpds, other tox reference cmpds, failed drugs, NTP in vivo, EPA high interest compounds, industrial, marketed drugs, fragrances, ...

ToxCast PhI&PhII chemicals:

Spanning diverse inventories of EPA interest




- 1060 Total chemicals → 2806 total overlaps across 16 diverse inventories (assigned in ACToR)
- Broad diversity of chemical structures & use types
- Large overlap with data-rich inventories


High-Throughput Screening 101 (HTS)



Robots




96-, 384-, 1536 Well Plates




Chemical Exposure




Cell Population




Pathway



Target Biology (e.g.,
Estrogen Receptor)



ToxCast Assays (>700 endpoints)



Assay Provider

ACEA
Apredica
Attagene
BioReliance
BioSeek
CeeTox
CellzDirect
Tox21/NCATS
NHEERL MESC
NHEERL Zebrafish
NovaScreen (Perkin Elmer)
Odyssey Thera
Vala Sciences

Biological Response

cell proliferation and death
cell differentiation
Enzymatic activity
mitochondrial depolarization
protein stabilization
oxidative phosphorylation
reporter gene activation
gene expression (qNPA)
receptor binding
receptor activity
steroidogenesis

Target Family

response Element
transporter
cytokines
kinases
nuclear receptor
CYP450 / ADME
cholinesterase
phosphatases
proteases
XME metabolism
GPCRs
ion channels

Assay Design

viability reporter
morphology reporter
conformation reporter
enzyme reporter
membrane potential reporter
binding reporter
inducible reporter

Readout Type

single
multiplexed
multiparametric

Cell Format

cell free
cell lines
primary cells
complex cultures
free embryos

Species

human
rat
mouse
zebrafish
sheep
boar
rabbit
cattle
guinea pig

Tissue Source

Lung	Breast
Liver	Vascular
Skin	Kidney
Cervix	Testis
Uterus	Brain
Intestinal	Spleen
Bladder	Ovary
Pancreas	Prostate
Inflammatory	Bone

Detection Technology

qNPA and ELISA
Fluorescence & Luminescence
Alamar Blue Reduction
Arraysan / Microscopy
Reporter gene activation
Spectrophotometry
Radioactivity
HPLC and HPEC
TR-FRET

ToxCast Phase II: 1051 Chemicals x 791 Assay Readouts

ACEA: red

Attagene: orange


Apredica: black

BioSeek: green

Novascreen: gray

Tox21: violet


OT: blue



Chemicals

Assays

80-05-7 : Bisphenol A



Most chemicals cause activity in many assays near the cytotoxicity threshold

Cell stress-related assay activity: “Burst”

“Hit” (AC50) in burst region is less likely to result from specific activity
(e.g. binding to receptor or enzyme)

Z-score: # of SD from burst center

-High Z: more likely to be specific

-Low Z: less likely to be specific

ToxCast Phase II: 1051 Chemicals x 791 Assay Readouts

ACEA: red

Attagene: orange



Apredica: black

BioSeek: green

Novascreen: gray

Tox21: violet

OT: blue



Most chemicals cause activity in many assays near the cytotoxicity threshold

Cell stress-related assay activity





“Hit” (AC50) in burst region is less likely to result from specific activity
(e.g. binding to receptor or enzyme)

Z-score: # of SD from burst center

-High Z: more likely to be specific

-Low Z: less likely to be specific

Significance of *In Vitro* Effects



Assay Target Class

Molecular Target

EDC
Acetylcholinesterase Inhibition
Ion channel blocker
Genotoxicity

Assessment

AOP Assessment
Targeted testing

Cell Stress Mediated

Oxidative stress
Membrane disruption
Nucleophiles
Electrophiles
Energy depletion





Estimate MTD
Estimate NOEL

No Effect

Non-reactive chemical
Not bioactive
Effects would require high doses

Estimate NOEL

Significance of *In Vitro* Effects



Assay Target Class

Molecular Target

EDC
Acetylcholinesterase Inhibition
Ion channel blocker
Genotoxicity

Assessment

AOP Assessment
Targeted testing

Cell Stress Mediated

Oxidative stress
Membrane disruption
Nucleophiles
Electrophiles
Energy depletion

Estimate MTD
Estimate NOEL

No Effect


Non-reactive chemical
Not bioactive
Effects would require high
doses

Estimate NOEL

How to summarize 1000s of chemicals x 100s of assays?


- Gene Score: Combine potency and specificity
 - Potency: $-\log(\text{AC}_{50})$
 - Specificity: Z-score
 - Gene score = Potency + Specificity
 - average over assays for gene $[-\log(\text{AC}_{50}) + \text{Z-score}]$
 - Can be used to get quick ranking of chemicals
 - Gene Score > 7 are most interesting
 - Z-score=2 and $\text{AC}_{50}=10 \mu\text{M}$
 - 5670 chemical-gene combinations >7 (~1%)
 - 281 Genes (out of 330)
 - 1231 Chemicals (out of 1877)

Use of HTS Results in an Adverse Outcome Pathway (AOP)



ToxCast and the Endocrine Disruptor Screening Program

EPA Research provides basis for improving the suite of assays and models to advance chemical prioritization and screening




Chemical Prioritization

Includes registration review timeline, physico-chemical properties, exposure estimates, *in vitro* assays and computer models (QSAR, expert systems, systems biology models).


Screening Decisions

Near Term = Incorporates HTS/*in silico* prioritization methods for post EDSP List 2
Intermediate = Run subset of T1S assays indicated by HTS and *in silico* predictions
Long Term = Full replacement of EDSP T1S Battery



Major theme – all assays have false positives and negative

Assays cluster by technology, suggesting technology-specific non-ER activity




Much of this “noise” is reproducible, i.e. it is “assay interference”

Result of interaction of chemical with complex biology in the assay

Our chemical library is only partially “drug-like”




- Solvents
- Surfactants
- Intentionally cytotoxic compounds
- Metals
- Inorganics



Example 1 – BPA – true agonist (AUC=0.66)

Assays

80-05-7 : Bisphenol A



Binding assays active at lowest concentration

AUC “sign” feature will discount this



Cytotoxicity Region: red line is median cytotox AC50

Example curves

True Agonist



80-05-7 : Bisphenol A

80-05-7 : Bisphenol A



82640-04-8 : Raloxifene hydrochloride



82640-04-8 : Raloxifene hydrochloride



Negative-Broad Assay Interference

868-85-9 : Dimethyl hydrogen phosphite



868-85-9 : Dimethyl hydrogen phosphite




Negative-Narrow Assay Interference

10016-20-3 : alpha-Cyclodextrin



10016-20-3 : alpha-Cyclodextrin



Reference Chemical Classification




AUC heat map for
Reference chemicals




Toxicity Reference Database (ToxRefDB)

- Holds *in vivo* endpoint data from animal toxicology studies
- Currently at 5567 studies on 1049 unique chemicals



Data Source	Study Count
EPA OPP_der	3279
Open Literature	731
National Toxicol Program	666
Sanofi_pharma	222
Unpublished_submissions	50
GSK_pharma	38
Health Canada PMRA_der	23


Predictive Model Development from ToxCast and Other Data




Reproductive Rat Toxicity Model Features

Chemicals

Ordered By
ReproToxModelScore



Reproductive Rat Toxicity Model Features



Predictive Toxicity Modeling Based on ToxCast Data

❖ Predictive models: **endpoints**

liver tumors: Judson et al. 2010, Env Hlth Persp 118: 485-492

hepatocarcinogenesis: Shah et al. 2011, PLoS One 6(2): e14584

cancer: Kleinstreuer et al. 2012, submitted

rat fertility: Martin et al. 2011, Biol Reprod 85: 327-339

rat-rabbit prenatal devtox: Sipes et al. 2011, Toxicol Sci 124: 109-127

zebrafish vs ToxRefDB: Sipes et al. 2011, Birth Defects Res C 93: 256-267

❖ Predictive models: **pathways**

endocrine disruption: Reif et al. 2010, Env Hlth Persp 118: 1714-1720

microdosimetry: Wambaugh and Shah 2010, PLoS Comp Biol 6: e1000756

mESC differentiation: Chandler et al. 2011, PLoS One 6(6): e18540


HTP risk assessment: Judson et al. 2011, Chem Res Toxicol 24: 451-462

angiogenesis: Kleinstreuer et al. 2011, Env Hlth Persp 119: 1596-1603

❖ Continuing To Expand & Validate Prediction Models

❖ Generally moving towards more mechanistic/AOP-based models

Beyond *in vitro* to *in vivo* signatures



Why is Chemistry needed?

Thomas et al, 2012, Tox Sci

- ToxCast Phase I library (309 cmpds)
- >80 statistical methods
- ToxRef DB endpoints
- No successful models of *in vivo* endpoints

Statistics

Noisy,
lack of
statistical power,
mechanistically
diverse dataset

EPA's modeling success
has relied upon use of
prior knowledge &
aggregation to focus
investigations into
productive areas


Model
in vivo
toxicity

Chemo-types
Alerts
Features

Chemistry

AOPs
MOA Pathways
Genes

HTS (>500 assays)
In vitro Biology



Toxicity Prediction Challenge:

Bringing all knowledge & data to bear on problem

Biologically-based QSAR & Cheminformatics

Reactivity & toxicity-
informed
features &
classes

Aggregation

Mechanistically
well-defined
toxicity endpoint

Data-mining

Adverse Outcomes:

- > Pathways
- > Genes
- > Assays
- + Statistical
associations

Structures

In Vitro/HTS

In Vivo

Existing knowledge

Understanding Success and Failure

- Why *In vitro* to *in vivo* can work:
 - Chemicals cause effects through direct molecular interactions that we can measure with *in vitro* assays
- Why *in vitro* to *in vivo* does not always work:
 - ★– Pharmacokinetics issues: biotransformation, clearance (FP, FN)
 - ★– Assay coverage: don't have all the right assays (FN)
 - ★– Tissue issues: may need multi-cellular networks and physiological signaling (FN)
 - ★– Statistical power issues: need enough chemicals acting through a given MOA to be able to build and test model (FN)
 - ★– Homeostasis: A multi-cellular system may adapt to initial insult (FP)
 - *In vitro* assays are not perfect! (FP, FN)
 - *In vivo* rodent data is not perfect! (FP, FN)

Systems
Models

ToxCast Phase II Data Release: December 2013

- ToxCast Assay Summary Activity Files (toxminer_v19b)
 - Rows of Chemicals, Columns of Assays, Intersection of AC50, EMAX
- ToxCast Assay Annotation Files (toxcast_assay_annotation_v1)
 - Assignment of assay design information
 - Assignment of target information (gene target)
- ToxCast Chemical Library & Structure Files (dsstox)
- ToxCast Concentration Response Data Files (toxminer_v19b)
 - Detailed files of normalized data (>50M Rows)
- ToxRefDB Effect & Endpoint Data Files (toxrefdb)
 - Flattened version of ToxRefDB with all effect information (>6000 studies & 1000 chemicals)
 - Endpoint summary file that has NEL/LEL and NOAEL/LOAEL across all studies

DATA EXPLORER


Assay List

Data Class	Assay Endpoint
ATG	ATG_ERa_TRANS
ATG	ATG_ERE_CIS
ATG	ATG_PPARG_TRANS
ATG	ATG_PPARE_CIS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS
ATG	ATG_ERa_TRANS

Summary Activity Table

CASRN	Chemical Name	Q	AC 50	T	B	W	Em ax
80-05-7	Bisphenol A						
80-05-1	Bisphenol B						
80-05-2	Bisphenol C						
80-05-3	Bisphenol D						
80-05-4	Bisphenol E						
80-05-5	Bisphenol F						
80-05-6	Bisphenol G						
80-05-8	Bisphenol H						
80-05-9	Bisphenol I						

CONC RESPONSE PLOT



Summary

- Goal: use *in vitro* assays to screen and prioritize many data-poor chemicals
- Signature generation uses combination of biological insight and statistics
- Initial models point the way to real-world applications
- Further refinements are in the works
 - More chemicals and assays
 - Use of chemoinformatics
 - Systems-level models
 - Targeted testing approaches



**EPA NATIONAL CENTER FOR COMPUTATIONAL TOXICOLOGY STAFF
FEBRUARY 5, 2013**